Friday, December 19, 2025 12/19/2025

Seeing the Unseen: High-Throughput Prospective Profiling and inhibition of SARS-CoV-2 receptor-binding domain variants

Award Number: R21AI174157
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/08/2022
PERIOD OF PERFORMANCE END DATE: 11/30/2025

Group Awards By:

View Award Description

Seeing the Unseen: High-Throughput Prospective Profiling and inhibition of SARS-CoV-2 receptor-binding domain variants - The ongoing rapid and widespread transmission of SARS-CoV-2 across the world has resulted in myriad viral strains, but human immunity has been acquired from vaccination against a single (Wuhan-Hu-1) strain and/or previous infection with a handful of strains. The large number of substitutions present in the recently emerged Omicron Variant of Concern (VOC) spike (S) protein's receptor-binding domain (RBD) – a key antigenic site – are associated with immune evasion and a putative broadening of species tropism. Immune evasion may have serious consequences, potentially leading to increased incidence of infection, reinfection and/or further enhancing viral fitness during uncontrolled spread around the globe. Omicron has not directly descended from any of the previously identified VOCs raising the specter of future, highly-substituted immune-evasive VOCs. Prior knowledge of the space of potential variants may enable the development of active and passive immunization strategies for blunting the damage caused by novel VOCs. However, the scientific community currently lacks the tools to prospectively identify novel highly-substituted VOCs capable of immune evasion. In Aim 1 we propose a pipeline for discovering a diverse set of heavily substituted and immune-evasive RBD variants. Relatedly, the medical community lacks binding-based therapeutic passive immunization leads against unknown future variants that can be deployed in the event of a novel VOC outbreak. For example, many monoclonal antibody therapies that previously received emergency use authorization from FDA no longer neutralize the Omicron VOC, leading to fewer clinically relevant pharmaceutical interventions. For Aim 2, we propose to redesign existing small-protein-based therapeutic entities to bind nearly all possible prospectively identified novel VOCs. Our proposal is enabled by results from the PI and co-I laboratories, in which we developed high-throughput structure-based computational and experimental approaches for predicting and characterizing the binding of diverse SARS-CoV-2 RBD variants with the ACE2 and a set of neutralizing antibodies (nAbs) to effectively recapitulate variant S function and immune evasion properties. We will apply our technologies to broadly sample heavily substituted (10-20 substitutions) but functional RBD variants and identify those that are predicted to abrogate binding to a representative set of neutralizing antibodies raised against two key (Class 1 and Class 2) epitope regions of the RBD. Experimentally validated classes of escape-competent RBD variants will serve as targets for the design of small protein-based inhibitors. The overall impact of this project will be the prospective identification of the space of possible variation in Class 1 and Class 2 epitopes that can still be recognized by the prevalent immune response. This will aid therapeutic intervention and identify candidate RBD variant immunogens for inclusion in next-generation vaccines. This project will also provide potent inhibitors of the diverse highly substituted RBD variants. With further clinical development, these may serve as off-the-shelf therapeutics for effectively stopping a new VOC in its tracks.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	RUTGERS, THE STATE UNIVERSITY	3 RUTGERS PLZ	NEW BRUNSWICK	NJ	08901	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	2	11/1/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $187,992 )
2024	2024	RUTGERS, THE STATE UNIVERSITY	3 RUTGERS PLZ	NEW BRUNSWICK	NJ	08901	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	2	11/15/2023	NON-COMPETING CONTINUATION	$169,193
2024	2024	RUTGERS, THE STATE UNIVERSITY	3 RUTGERS PLZ	NEW BRUNSWICK	NJ	08901	MIDDLESEX	USA	Allergy and Infectious Diseases Research	001	2	5/14/2024	NON-COMPETING CONTINUATION	$18,799
														Subtotal = $187,992

Issue Date FY: 2023 ( Subtotal = $236,919 )
2023	2023	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	3 RUTGERS PLZA	NEW BRUNSWICK	NJ	08901	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	1	12/6/2022	NEW	$236,919
														Subtotal = $236,919

Grand Total All Awards = $424,911

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Seeing the Unseen: High-Throughput Prospective Profiling and inhibition of SARS-CoV-2 receptor-binding domain variants

Award Number: R21AI174157

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/08/2022

PERIOD OF PERFORMANCE END DATE: 11/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer